Top

Published in:

01-10-2011 | Original paper

The association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study

Authors: Wildon R. Farwell, Christopher Lourenco, Erika Holmberg, Robert B. Hall, Leonard D’Avolio, Elizabeth V. Lawler, J. Michael Gaziano

Published in: Cancer Causes & Control | Issue 10/2011

Abstract

Objective

We examined the relationship between height and prostate cancer grade.

Methods

The Early Stage Prostate Cancer Cohort Study is an observational cohort of 1,037 men diagnosed with early-stage prostate cancer, T_0–3N_xM₀. High-grade prostate cancer was defined as a biopsy Gleason score ≥ 7 (4 + 3). Logistic regression models were created to calculate odds ratios (OR) and 95% confidence intervals (CI) for the cross-sectional relationship between height and prostate cancer grade in the overall cohort and subpopulations.

Results

We identified 939 participants with a biopsy Gleason score. High-grade prostate cancer was diagnosed in 138 participants. Overall, participants in the highest quartile of height were more than twice as likely to have a Gleason score ≥ 7 (4 + 3) than participants in the lowest quartile of height, OR 2.14 (95% CI 1.11, 4.14), after multivariate adjustment. Participants in the highest quartile of height were more likely to be diagnosed with high-grade prostate cancer than participants in the lowest quartile of height among participants who were black, OR 8.00 (95% CI 1.99, 32.18), and participants who had diabetes mellitus, OR 5.09 (95% CI 1.30, 19.98).

Conclusions

Height is associated with increased risk of high-grade prostate cancer overall and perhaps among certain subpopulations.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin. 60:277–300PubMedCrossRef

Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 274:626–631PubMedCrossRef

Andrén O, Fall K, Franzén L, Andersson S, Johannson J, Rubin MA (2006) How well does the Gleason score predict prostate cancer death? A 20 year followup of a population based cohort in Sweden. J Urol 175:1337–1340PubMedCrossRef

Zuccolo L, Harris R, Gunnell D et al (2008) Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 17(9):2325–2336PubMedCrossRef

Ahn J, Moore SC, Albanes D, Huang WY, Leitzmann MF, Hayes RB (2009) Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Br J Cancer 101:522–525PubMedCrossRef

Sequoia JSP, Wright ME, McCarron P et al (2006) A prospective investigation of height and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 15(11):2174–2178PubMedCrossRef

Chen HL, Miller BA, Giovannuci E, Hayes RB (2003) Height and the survival of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 12:215–218PubMed

Freeman VL, Liao Y, Durazo-Arvizu R, Cooper RS (2001) Height and risk of fatal prostate cancer: findings from the National Health Interview Survey (1986 to 1994). Ann Epidemiol 11:21–27CrossRef

D’Avolio LD, Farwell WR, Nguyen TM et al (2010) Evaluation of a generalizable approach to clinical information retrieval using the Automated Retrieval Console (ARC). JAMIA 17:375–382PubMed

10.

Epstein JI, Allsbrook WC, Amin MB, Egevad LL (2005) The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242PubMedCrossRef

11.

Juul A, Bang P, Hertel NT et al (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78(3):744–752PubMedCrossRef

12.

Signorello LB, Kuper H, Lagiou P et al (2000) Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 9:173–178PubMedCrossRef

13.

Gapstur SM, Kopp P, Chiu BCH, Gann PH, Colangelo LA, Liu K (2004) Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-1 and IGF binding protein-3 levels in black and white men: the CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 13(12):2208–2216PubMed

14.

Gunnell D, Oliver SE, Donovan JL, Peters TJ, Gillatt D, Persad R et al (2004) Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab 89:213–218PubMedCrossRef

15.

Goodman-Gruen D, Barrett-Connor E (1997) Epidemiology of insulin-like growth factor-1 in elderly men and women, the Rancho Bernardo Study. Am J Epidemiol 145:970–976PubMed

16.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244PubMedCrossRef

17.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRef

18.

Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–488PubMed

19.

Silventoinen K, Sammalisto S, Perola AM et al (2003) Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res 6:399–408PubMedCrossRef

20.

Sherlock M, Toogood AA (2007) Aging and the growth hormone/insulin like growth factor-I axis. Pituitary 10:189–203PubMedCrossRef

21.

McGreevy K, Hoel B, Lipsitz S, Bissada N, Hoel D (2005) Racial and anthropometric differences in plasma levels of insulin-like growth factor 1 and insulin-like growth factor binding protein-3. Urology 66:587–592PubMedCrossRef

22.

Platz EA, Pollak MN, Rimm EB et al (1999) Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8:1107–1110PubMed

23.

Tricoli JV, Winter DL, Hanlon AL et al (1999) Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54:178–182PubMedCrossRef

24.

DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, LeMarchand L (2004) Dietary and lifestyle correlates of plasma insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 13(9):1444–1451PubMed

25.

Winter DL, Hanlon AL, Raysor SL et al (2001) Plasma levels of IFG-1, IGF-2, and IGFBP-3 in white and African-american men at increased risk of prostate cancer. Urology 58:614–618PubMedCrossRef

26.

Frystyk J, Skjærbæk C, Vestbo E, Fisker S, Ørskov H (1999) Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 15(5):314–322PubMedCrossRef

27.

Heald AH, Cruickshank JK, Riste LK et al (2001) Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetalogica 44:333–339CrossRef

28.

Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannuci E (2008) Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Conrol 19:703–710CrossRef

29.

Spencer EA, Appleby PN, Davey GK, Key TJ (2002) Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr 5(4):561–565PubMedCrossRef

30.

Greenland S (1998) Introduction to Regression Models. In: Rothman KJ, Greenland S (eds) Modern Epidemiology, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 386–389

Title: The association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study
Authors: Wildon R. Farwell
Christopher Lourenco
Erika Holmberg
Robert B. Hall
Leonard D’Avolio
Elizabeth V. Lawler
J. Michael Gaziano
Publication date: 01-10-2011
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-011-9820-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2011

Mediators and moderators of the effects of a year-long exercise intervention on endogenous sex hormones in postmenopausal women

Birth size and breast cancer risk among young California-born women

Association of circulating VacA-neutralizing antibodies with gastric cancer and duodenal ulcer

Dietary fiber and grain consumption in relation to head and neck cancer in the NIH-AARP Diet and Health Study

The determinants of serum vitamin D levels in participants in a melanoma case–control study living in a temperate climate

The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case–control study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer